secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0000950170-21-001172
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO
-------------------------------------------------------------------

- Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.
- Cash and short-term investments of $394.2M at June 30, 2021 vs $7.8M at Dec 31, 2020.
- Q2 net loss of $6.2M, compared to $2.5M in same period 2020; R&D expense $4.7M.
- On track to submit at least two INDs by end of 2022 for lead TRACTr programs.
- Appointed Shahram Salek-Ardakani as CSO and Wayne Godfrey as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/0000950170-21-001172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021001172/janx-20210810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer